株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

完全置換型人工心臓の世界市場:医療機器のパイプライン評価

Total Artificial Heart - Medical Devices Pipeline Assessment, 2019

発行 GlobalData 商品コード 358225
出版日 ページ情報 英文 68 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.33円で換算しております。
Back to Top
完全置換型人工心臓の世界市場:医療機器のパイプライン評価 Total Artificial Heart - Medical Devices Pipeline Assessment, 2019
出版日: 2019年12月17日 ページ情報: 英文 68 Pages
概要

当レポートでは、世界の完全人工心臓市場における、主要なパイプライン製品 (医療機器) とその治験の進行状況について調査すると共に、製品の機能・特性の比較分析 (治験の進行段階別) や、主要企業のプロファイルおよび代表的製品、昨今の市場動静 (業績報告・資本取引動向など) といった情報を取りまとめてお届けいたします。

第1章 目次

第2章 イントロダクション

  • 完全置換型人工心臓の概要

第3章 治験中の製品

  • パイプライン製品:治験段階別
  • パイプライン製品:地域別
  • パイプライン製品:規制経路別
  • パイプライン製品:推定認証時期別
  • 現在進行中の治験

第4章 治験中のパイプライン製品:企業別

  • 完全置換型人工心臓の企業:治験段階別のパイプライン製品
  • 完全置換型人工心臓:治験段階別のパイプライン製品

第5章 完全置換型人工心臓市場:企業・製品の概要

  • Abiomed, Inc.
  • BiVacor Pty Ltd
  • Carmat SAS
  • Cleveland Heart, Inc.
  • Foster-Miller, Inc. (Inactive)
  • MicroMed Cardiovascular, Inc.
  • SynCardia Systems, Inc.
  • 東京大学

第6章 完全置換型人工心臓市場:昨今の動向

第7章 付録

図表一覧

図表

List of Tables

  • Table 1: Total Artificial Heart - Pipeline Products by Stage of Development
  • Table 2: Total Artificial Heart - Pipeline Products by Territory
  • Table 3: Total Artificial Heart - Pipeline Products by Regulatory Path
  • Table 4: Total Artificial Heart - Pipeline Products by Estimated Approval Date
  • Table 5: Total Artificial Heart - Ongoing Clinical Trials
  • Table 6: Total Artificial Heart Companies - Pipeline Products by Stage of Development
  • Table 7: Total Artificial Heart - Pipeline Products by Stage of Development
  • Table 8: Abiomed Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 9: AbioCor II - Product Status
  • Table 10: AbioCor II - Product Description
  • Table 11: BiVacor Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 12: BiVACOR Device - Product Status
  • Table 13: BiVACOR Device - Product Description
  • Table 14: Carmat SAS Pipeline Products & Ongoing Clinical Trials Overview
  • Table 15: Artificial Heart - Product Status
  • Table 16: Artificial Heart - Product Description
  • Table 17: Carmat SAS - Ongoing Clinical Trials Overview
  • Table 18: Artificial Heart - Carmat Total Artificial Heart Early Feasibility Study
  • Table 19: Artificial Heart - Clinical Evaluation of the Carmat Total Artificial Heart for Patients with Advanced Heart Failure
  • Table 20: Cleveland Clinic Lerner College of Medicine Pipeline Products & Ongoing Clinical Trials Overview
  • Table 21: Continuous-Flow Total Artificial Heart - Product Status
  • Table 22: Continuous-Flow Total Artificial Heart - Product Description
  • Table 23: Pediatric Continuous-Flow Total Artificial Heart - Product Status
  • Table 24: Pediatric Continuous-Flow Total Artificial Heart - Product Description
  • Table 25: Cleveland Heart Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 26: SmartHeart TAH - Product Status
  • Table 27: SmartHeart TAH - Product Description
  • Table 28: Foster-Miller Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
  • Table 29: MagScrew Total Artificial Heart - Product Status
  • Table 30: MagScrew Total Artificial Heart - Product Description
  • Table 31: Indian Institute of Technology Kharagpur Pipeline Products & Ongoing Clinical Trials Overview
  • Table 32: Artificial Heart - Product Status
  • Table 33: Artificial Heart - Product Description
  • Table 34: Lausanne University Hospital Pipeline Products & Ongoing Clinical Trials Overview
  • Table 35: RollingHeart - Product Status
  • Table 36: RollingHeart - Product Description
  • Table 37: OregonHeart Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
  • Table 38: Next Generation Total Artificial Heart - Product Status
  • Table 39: Next Generation Total Artificial Heart - Product Description
  • Table 40: ReliantHeart, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 41: Pulse Less Total Artificial Heart - Product Status
  • Table 42: Pulse Less Total Artificial Heart - Product Description
  • Table 43: Scandinavian Real Heart AB Pipeline Products & Ongoing Clinical Trials Overview
  • Table 44: Total Artificial Heart - Product Status
  • Table 45: Total Artificial Heart - Product Description
  • Table 46: Syncardia Systems LLC Pipeline Products & Ongoing Clinical Trials Overview
  • Table 47: SynCardia 50cc Temporary Total Artificial Heart - Adult Bridge To Transplant - Product Status
  • Table 48: SynCardia 50cc Temporary Total Artificial Heart - Adult Bridge To Transplant - Product Description
  • Table 49: SynCardia 50cc Temporary Total Artificial Heart - Destination Therapy - Product Status
  • Table 50: SynCardia 50cc Temporary Total Artificial Heart - Destination Therapy - Product Description
  • Table 51: SynCardia 50cc Temporary Total Artificial Heart - Pediatric Bridge To Transplant - Product Status
  • Table 52: SynCardia 50cc Temporary Total Artificial Heart - Pediatric Bridge To Transplant - Product Description
  • Table 53: SynCardia 70cc Temporary Total Artificial Heart - Destination Therapy - Product Status
  • Table 54: SynCardia 70cc Temporary Total Artificial Heart - Destination Therapy - Product Description
  • Table 55: Syncardia Systems LLC - Ongoing Clinical Trials Overview
  • Table 56: SynCardia 70cc Temporary Total Artificial Heart - Destination Therapy - SynCardia 70cc Temporary Total Artificial Heart (TAH-t) for Destination Therapy (DT)
  • Table 57: SynCardia 50cc Temporary Total Artificial Heart - Adult Bridge To Transplant - SynCardia 50cc Temporary Total Artificial Heart (TAH-t) as a Bridge to Transplant
  • Table 58: TEDA International Cardiovascular Hospital Pipeline Products & Ongoing Clinical Trials Overview
  • Table 59: Artificial Heart - Product Status
  • Table 60: Artificial Heart - Product Description
  • Table 61: University of Tokyo Pipeline Products & Ongoing Clinical Trials Overview
  • Table 62: Helical Flow Total Artificial Heart - Product Status
  • Table 63: Helical Flow Total Artificial Heart - Product Description
  • Table 64: Yale University Pipeline Products & Ongoing Clinical Trials Overview
  • Table 65: Corisma - Product Status
  • Table 66: Corisma - Product Description
  • Table 67: Glossary

List of Figures

  • Figure 1: Total Artificial Heart - Pipeline Products by Stage of Development
  • Figure 2: Total Artificial Heart - Pipeline Products by Territory
  • Figure 3: Total Artificial Heart - Pipeline Products by Regulatory Path
  • Figure 4: Total Artificial Heart - Pipeline Products by Estimated Approval Date
  • Figure 5: Total Artificial Heart - Ongoing Clinical Trials
目次
Product Code: GDME0867EPD

GlobalData's Medical Devices sector report, "Total Artificial Heart - Medical Devices Pipeline Assessment, 2019" provides an overview of Total Artificial Heart currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Total Artificial Heart pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Total Artificial Heart under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Total Artificial Heart and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Total Artificial Heart under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

  • 1.1 List of Tables 4
  • 1.2 List of Figures 5

2 Introduction 6

  • 2.1 Total Artificial Heart Overview 6

3 Products under Development 7

  • 3.1 Total Artificial Heart - Pipeline Products by Stage of Development 7
  • 3.2 Total Artificial Heart - Pipeline Products by Territory 8
  • 3.3 Total Artificial Heart - Pipeline Products by Regulatory Path 9
  • 3.4 Total Artificial Heart - Pipeline Products by Estimated Approval Date 10
  • 3.5 Total Artificial Heart - Ongoing Clinical Trials 11

4 Total Artificial Heart - Pipeline Products under Development by Companies 12

  • 4.1 Total Artificial Heart Companies - Pipeline Products by Stage of Development 12
  • 4.2 Total Artificial Heart - Pipeline Products by Stage of Development 13

5 Total Artificial Heart Companies and Product Overview 14

  • 5.1 Abiomed Inc Company Overview 14
    • 5.1.1 Abiomed Inc Pipeline Products & Ongoing Clinical Trials Overview 14
  • 5.2 BiVacor Pty Ltd Company Overview 15
    • 5.2.1 BiVacor Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 15
  • 5.3 Carmat SAS Company Overview 16
    • 5.3.1 Carmat SAS Pipeline Products & Ongoing Clinical Trials Overview 16
  • 5.4 Cleveland Clinic Lerner College of Medicine Company Overview 20
    • 5.4.1 Cleveland Clinic Lerner College of Medicine Pipeline Products & Ongoing Clinical Trials Overview 20
  • 5.5 Cleveland Heart Inc Company Overview 22
    • 5.5.1 Cleveland Heart Inc Pipeline Products & Ongoing Clinical Trials Overview 22
  • 5.6 Foster-Miller Inc (Inactive) Company Overview 23
    • 5.6.1 Foster-Miller Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 23
  • 5.7 Indian Institute of Technology Kharagpur Company Overview 24
    • 5.7.1 Indian Institute of Technology Kharagpur Pipeline Products & Ongoing Clinical Trials Overview 24
  • 5.8 Lausanne University Hospital Company Overview 25
    • 5.8.1 Lausanne University Hospital Pipeline Products & Ongoing Clinical Trials Overview 25
  • 5.9 OregonHeart Inc (Inactive) Company Overview 26
    • 5.9.1 OregonHeart Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 26
  • 5.10 ReliantHeart, Inc. Company Overview 27
    • 5.10.1 ReliantHeart, Inc. Pipeline Products & Ongoing Clinical Trials Overview 27
  • 5.11 Scandinavian Real Heart AB Company Overview 28
    • 5.11.1 Scandinavian Real Heart AB Pipeline Products & Ongoing Clinical Trials Overview 28
  • 5.12 Syncardia Systems LLC Company Overview 29
    • 5.12.1 Syncardia Systems LLC Pipeline Products & Ongoing Clinical Trials Overview 29
  • 5.13 TEDA International Cardiovascular Hospital Company Overview 36
    • 5.13.1 TEDA International Cardiovascular Hospital Pipeline Products & Ongoing Clinical Trials Overview 36
  • 5.14 University of Tokyo Company Overview 37
    • 5.14.1 University of Tokyo Pipeline Products & Ongoing Clinical Trials Overview 37
  • 5.15 Yale University Company Overview 38
    • 5.15.1 Yale University Pipeline Products & Ongoing Clinical Trials Overview 38

6 Total Artificial Heart- Recent Developments 39

  • 6.1 Nov 27, 2019: CARMAT appoints Alexandre Eleonore as director of manufacturing 39
  • 6.2 Nov 19, 2019: CARMAT granted authorization to resume the PIVOTAL study in the Czech Republic 39
  • 6.3 Nov 13, 2019: Micron Solutions reports 2019 third quarter results 40
  • 6.4 Nov 06, 2019: CARMAT: the feedback after 6 years and 8 months of cumulative support shows a constant improvement in the clinical outcomes of patients in the PIVOTAL study 40
  • 6.5 Oct 31, 2019: Abiomed announces Q2 FY 2020 revenue of $205 million and 29.4% operating margin 41

7 Appendix 65

  • 7.1 Methodology 65
  • 7.2 About GlobalData 68
  • 7.3 Contact Us 68
  • 7.4 Disclaimer 68
Back to Top